Researchers at the Yong Loo Lin School of Medicine, National University of Singapore, and NHG Health’s Institute of Mental Health have identified distinct changes in brain network organisation among individuals at clinical high risk for psychosis, providing new insights on how early alterations in brain connectivity may contribute to the development of the disorder.

In an innovative twist to sustainable agriculture, a new study reveals how sugarcane waste can be transformed into biochar—a powerful soil amendment that enhances soil quality. This research not only highlights a green approach to waste management but also provides a significant boost to soil health, offering a win-win for both the environment and farming practices.

The topics of human-level artificial general intelligence (AGI) and artificial superintelligence (ASI) have captivated researchers for decades. Interest has surged with the rapid progress and deployment of large language models (LLMs), which now handle tasks such as coding, scientific explanation, creative writing, and multimodal reasoning. “Solve AI and it will solve everything” remains a popular, if contested, credo—driving large-scale investment, shaping public narratives, and motivating optimism about transformative advances.

Applying this vision to the healthcare and pharmaceutical industries, Insilico Medicine—a leading generative AI-driven drug discovery company — defines the pharmaceutical superintelligence (PSI) as the next step of AI-driven drug discovery, it showcases a fully-autonomous platform capable of discovering and designing a perfect small molecule or a biologic drug, together with the biomarker for patient selection, producing a significant disease-modifying or curative response for any disease without failure and without the need for further human experimentation.

Working toward this ultimate goal, Insilico continuously upgrades its Pharma.AI platform by integrating state-of-the-art algorithms, expanding and refining its data sources, and validating its models in real-world case studies. Recently, Insilico announced the final 2025 edition of its Pharma.AI Updates, scheduled for December 10, 2025, from 10:00 to 11:00 a.m. ET. This webinar will provide an in-depth look at major updates across key applications, including PandaOmics, Generative Biologics, Chemistry42, and Science42: DORA, through interactive demos and real-world case studies.

"We undertook this difficult study to understand fatigue," said senior author Daniel Forger, a University of Michigan professor of mathematics. "We're seeing profound changes in the brain over the course of the day as we stay awake and they seem to be corrected as we go to sleep."